Absolute and relative activities of platinum-complexes on human tumors as evaluated by an antimetabolic in vitro assay

Maria Grazia Daidone, Rosella Silvestrini, Nadia Zaffaroni, Egle Grignolio, Fabio Landoni

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

An in vitro assay, which evaluates drug effect on 3H-thymidine incorporation, was used to investigate the absolute and relative activities of cisplatin (DDP), carboplatin (CBDCA) and iproplatin (CHIP) on 317 specimens from untreated tumors, including breast and ovarian cancers and malignant melanomas. Similar activities were generally observed for DDP and CHIP, whereas CBDCA exhibited a lower, although not significantly different cytotoxicity on breast and ovarian cancers. The relative activities of Platinum analogues were analyzed on 239 two-way drug sensitivity comparisons. The overall agreement rates ranged from 80.2 to 83.9% for the different comparisons. High coresistance, from 61.1 to 93.8%, was observed for all the comparisons, regardless of the tumor type. Cosensitivity rates were poor for breast and ovarian cancers, from 0 to 37.5%, whereas for melanomas an association in sensitivity was observed in 80% of the cases.

Original languageEnglish
Pages (from-to)245-250
Number of pages6
JournalInvestigational New Drugs
Volume5
Issue number3
DOIs
Publication statusPublished - Sep 1987

Fingerprint

Carboplatin
Platinum
Ovarian Neoplasms
Breast Neoplasms
Melanoma
Neoplasms
Pharmaceutical Preparations
Thymidine
Cisplatin
In Vitro Techniques

Keywords

  • antimetabolic assay
  • carboplatin
  • cisplatin
  • iproplatin

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine

Cite this

Absolute and relative activities of platinum-complexes on human tumors as evaluated by an antimetabolic in vitro assay. / Daidone, Maria Grazia; Silvestrini, Rosella; Zaffaroni, Nadia; Grignolio, Egle; Landoni, Fabio.

In: Investigational New Drugs, Vol. 5, No. 3, 09.1987, p. 245-250.

Research output: Contribution to journalArticle

@article{04b0966929924bed848c857d3c700868,
title = "Absolute and relative activities of platinum-complexes on human tumors as evaluated by an antimetabolic in vitro assay",
abstract = "An in vitro assay, which evaluates drug effect on 3H-thymidine incorporation, was used to investigate the absolute and relative activities of cisplatin (DDP), carboplatin (CBDCA) and iproplatin (CHIP) on 317 specimens from untreated tumors, including breast and ovarian cancers and malignant melanomas. Similar activities were generally observed for DDP and CHIP, whereas CBDCA exhibited a lower, although not significantly different cytotoxicity on breast and ovarian cancers. The relative activities of Platinum analogues were analyzed on 239 two-way drug sensitivity comparisons. The overall agreement rates ranged from 80.2 to 83.9{\%} for the different comparisons. High coresistance, from 61.1 to 93.8{\%}, was observed for all the comparisons, regardless of the tumor type. Cosensitivity rates were poor for breast and ovarian cancers, from 0 to 37.5{\%}, whereas for melanomas an association in sensitivity was observed in 80{\%} of the cases.",
keywords = "antimetabolic assay, carboplatin, cisplatin, iproplatin",
author = "Daidone, {Maria Grazia} and Rosella Silvestrini and Nadia Zaffaroni and Egle Grignolio and Fabio Landoni",
year = "1987",
month = "9",
doi = "10.1007/BF00175294",
language = "English",
volume = "5",
pages = "245--250",
journal = "Investigational New Drugs",
issn = "0167-6997",
publisher = "Kluwer Academic Publishers",
number = "3",

}

TY - JOUR

T1 - Absolute and relative activities of platinum-complexes on human tumors as evaluated by an antimetabolic in vitro assay

AU - Daidone, Maria Grazia

AU - Silvestrini, Rosella

AU - Zaffaroni, Nadia

AU - Grignolio, Egle

AU - Landoni, Fabio

PY - 1987/9

Y1 - 1987/9

N2 - An in vitro assay, which evaluates drug effect on 3H-thymidine incorporation, was used to investigate the absolute and relative activities of cisplatin (DDP), carboplatin (CBDCA) and iproplatin (CHIP) on 317 specimens from untreated tumors, including breast and ovarian cancers and malignant melanomas. Similar activities were generally observed for DDP and CHIP, whereas CBDCA exhibited a lower, although not significantly different cytotoxicity on breast and ovarian cancers. The relative activities of Platinum analogues were analyzed on 239 two-way drug sensitivity comparisons. The overall agreement rates ranged from 80.2 to 83.9% for the different comparisons. High coresistance, from 61.1 to 93.8%, was observed for all the comparisons, regardless of the tumor type. Cosensitivity rates were poor for breast and ovarian cancers, from 0 to 37.5%, whereas for melanomas an association in sensitivity was observed in 80% of the cases.

AB - An in vitro assay, which evaluates drug effect on 3H-thymidine incorporation, was used to investigate the absolute and relative activities of cisplatin (DDP), carboplatin (CBDCA) and iproplatin (CHIP) on 317 specimens from untreated tumors, including breast and ovarian cancers and malignant melanomas. Similar activities were generally observed for DDP and CHIP, whereas CBDCA exhibited a lower, although not significantly different cytotoxicity on breast and ovarian cancers. The relative activities of Platinum analogues were analyzed on 239 two-way drug sensitivity comparisons. The overall agreement rates ranged from 80.2 to 83.9% for the different comparisons. High coresistance, from 61.1 to 93.8%, was observed for all the comparisons, regardless of the tumor type. Cosensitivity rates were poor for breast and ovarian cancers, from 0 to 37.5%, whereas for melanomas an association in sensitivity was observed in 80% of the cases.

KW - antimetabolic assay

KW - carboplatin

KW - cisplatin

KW - iproplatin

UR - http://www.scopus.com/inward/record.url?scp=0023256547&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023256547&partnerID=8YFLogxK

U2 - 10.1007/BF00175294

DO - 10.1007/BF00175294

M3 - Article

VL - 5

SP - 245

EP - 250

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

IS - 3

ER -